Tirzepatide and Obstructive Sleep Apnoea: What SURMOUNT-OSA Measured, the Role of Weight Loss, and What Remains Open

RESEARCH · TIRZEPATIDE · OBSTRUCTIVE SLEEP APNOEA

Tirzepatide and Obstructive Sleep Apnoea: What SURMOUNT-OSA Measured, the Role of Weight Loss, and What Remains Open

PurixLab’s Tirzepatide 10mg is a research vial of the dual GIP/GLP-1 receptor agonist. Our earlier articles cover the SURPASS and SURMOUNT programme, body composition and liver fat and withdrawal and weight regain. This article looks at a different clinical endpoint: obstructive sleep apnoea (OSA), where the SURMOUNT-OSA trials measured breathing during sleep rather than body weight as the primary outcome. These are published clinical-trial findings about the drug under medical supervision; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.

Why weight was the starting hypothesis

The link between body weight and sleep-disordered breathing was established long before incretin drugs. In a population cohort of six hundred and ninety employed Wisconsin residents studied twice at 4-year intervals, a 10% weight loss predicted an approximate 26% decrease in the apnoea-hypopnoea index (AHI), and a 10% weight gain an approximate 32% increase [1]. Imaging work suggested where the effect sits: in 67 people with obesity and OSA scanned before and after lifestyle or surgical weight loss, reductions in tongue fat correlated with AHI reductions and were the primary upper-airway mediator of the relationship [2].

The AHI is a frequency count, and it predicts outcomes poorly. In two cohorts, the Osteoporotic Fractures in Men Study (2743 men) and the Sleep Heart Health Study (5111 adults), the “hypoxic burden”, the area under the oxygen-desaturation curve linked to respiratory events, predicted cardiovascular mortality where the AHI did not [3]. An earlier proof-of-concept incretin trial in OSA was SCALE Sleep Apnea, in people with obesity who were unwilling or unable to use CPAP: after 32 weeks, the AHI fell by 12.2 events per hour with liraglutide and 6.1 with placebo [4].

How SURMOUNT-OSA was designed

SURMOUNT-OSA was a master protocol of two 52-week, placebo-controlled trials in adults with moderate-to-severe OSA (AHI of at least 15 events per hour) and obesity (BMI of at least 30). One appendix enrolled people not using positive airway pressure (PAP; n = 234) and the other people already using it (n = 235); all participants also received lifestyle intervention, and wearable home sleep testing was added for exploratory outcomes [5]. In the PAP trial, PAP was withdrawn before polysomnography and questionnaire assessments, so both trials measured untreated breathing [6].

The primary results

At baseline, the mean AHI was 51.5 and 49.5 events per hour and the mean BMI 39.1 and 38.7 in the two trials. At week 52, the AHI changed by -25.3 events per hour with tirzepatide against -5.3 with placebo in the first trial (estimated difference -20.0), and by -29.3 against -5.5 in the PAP trial (difference -23.8). All prespecified key secondary endpoints, including body weight, hypoxic burden, high-sensitivity C-reactive protein (hsCRP), systolic blood pressure and patient-reported sleep impairment, improved relative to placebo. The most frequent adverse events were gastrointestinal and mostly mild to moderate, and the programme was funded by Eli Lilly [7].

How much of the effect is weight loss?

A post hoc time-course analysis found that peripheral AHI from home monitoring improved versus baseline as early as week 4, but the difference from placebo did not become significant until week 20 for both peripheral AHI and hypoxic burden. The size of AHI and hypoxic-burden changes tracked achieved weight reduction in both trials, and the authors stated that further research is needed to separate weight loss from other effects [8]. A second post hoc analysis grouped all 469 participants by weight reduction at week 20 (under 5%, 5% to 10%, 10% to 15%, and 15% or more); those losing at least 15% early had greater AHI improvement at week 52 [9].

Mediation modelling of cardiometabolic markers gave a more mixed picture. Changes in OSA metrics had an independent mediating effect on hsCRP, insulin resistance (HOMA-IR) and triglycerides; weight alone, or weight plus OSA metrics, mediated the systolic blood-pressure change; and neither mediated diastolic pressure [10]. Physiology data are sparse. One case report from the trial, a 35-year-old man whose BMI fell from 31.0 to 24.9 and whose AHI fell from 54.8 to 4.4, described improved upper-airway patency, greater pharyngeal muscle responsiveness and reduced loop gain [11]. One participant cannot establish a mechanism, and a 2026 review notes that weight-loss-related anatomical unloading has not yet been confirmed by serial upper-airway imaging, critical-closing-pressure measurement or physiological endotyping in incretin-treated cohorts [12].

Subgroups and patient-reported outcomes

Descriptive subgroup analyses reported AHI reductions regardless of baseline age, sex, AHI severity, BMI or neck circumference; 68% to 79% of tirzepatide-treated participants moved to a better severity category, while 64% to 70% of the placebo group saw no clinically relevant change [13]. Questionnaire endpoints, including PROMIS sleep-related impairment and sleep disturbance and the Functional Outcomes of Sleep Questionnaire, favoured tirzepatide [6], and participants with worse baseline fatigue, sleepiness or sleep quality showed larger questionnaire improvements, although the objective changes were similar across symptom subgroups [14]. Qualitative exit interviews with seventy US-based and 12 Germany-based participants add context but are not blinded efficacy data [15].

From risk markers to outcomes

None of these trials measured cardiovascular events. A 2024 commentary estimated a possible cardiovascular benefit indirectly, from the reduction in hypoxic burden [16], and a retrospective TriNetX cohort associated GLP-1 receptor agonist exposure in OSA with lower hazards of stroke and mortality, with directionally consistent tirzepatide subgroup results; the authors call these findings hypothesis-generating [17]. Pooled analyses also urge caution: a meta-analysis of 6 trials (1,069 participants) found an AHI reduction of 9.99 events per hour but substantial heterogeneity, and concluded that these drugs are not established substitutes for CPAP [18], while a network meta-analysis of thirty-four trials found the largest AHI reduction with CPAP rather than with any incretin agent [19].

What remains open

  • Duration. The randomised data cover 52 weeks of treatment [7].
  • Mechanism. How much of the AHI change is weight-independent is unresolved [8,12].
  • Hard outcomes. Cardiovascular benefit in OSA is inferred from markers and observational data, not trial events [16,17].
  • Independence. The trial and its post hoc analyses were funded by the manufacturer [7,9].

Tirzepatide 10mg at PurixLab

Tirzepatide 10mg: a labelled lyophilized research vial with 10mg per vial, C$129 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tirzepatide-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View Tirzepatide 10mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015-21. PubMed 11122588 · doi:10.1001/jama.284.23.3015
  2. Wang SH, Keenan BT, Wiemken A, et al. Effect of Weight Loss on Upper Airway Anatomy and the Apnea-Hypopnea Index. The Importance of Tongue Fat. Am J Respir Crit Care Med. 2020;201(6):718-727. PubMed 31918559 · PMC7068828 · doi:10.1164/rccm.201903-0692OC
  3. Azarbarzin A, Sands SA, Stone KL, et al. The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study. Eur Heart J. 2019;40(14):1149-1157. PubMed 30376054 · PMC6451769 · doi:10.1093/eurheartj/ehy624
  4. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-9. PubMed 27005405 · PMC4973216 · doi:10.1038/ijo.2016.52
  5. Malhotra A, Bednarik J, Chakladar S, et al. Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial. Contemp Clin Trials. 2024;141:107516. PubMed 38547961 · PMC11168245 · doi:10.1016/j.cct.2024.107516
  6. Kanu C, Shinde S, Chakladar S, et al. Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity. Sleep Med. 2025;134:106719. PubMed 40774158 · PMC12720398 · doi:10.1016/j.sleep.2025.106719
  7. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. PubMed 38912654 · PMC11598664 · doi:10.1056/NEJMoa2404881
  8. Malhotra A, Grunstein RR, Azarbarzin A, et al. Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight. Sleep Med. 2025;136:106853. PubMed 41135142 · PMC12723708 · doi:10.1016/j.sleep.2025.106853
  9. Lin YN, Sun XW, Dai SJ, et al. Association between early body weight reduction and treatment outcomes in participants with obstructive sleep apnoea and obesity: a post hoc analysis of SURMOUNT-OSA trials. EClinicalMedicine. 2026;100:104203. PubMed 42774617 · PMC13595002 · doi:10.1016/j.eclinm.2026.104203
  10. Malhotra A, Grunstein R, Azarbarzin A, et al. Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. Nat Med. 2026;32(2):653-659. PubMed 41540105 · PMC12920140 · doi:10.1038/s41591-025-04071-1
  11. Hsu Y, Cheng WJ, Finnsson E, et al. Endotypic Trait Responses to 12-Month Tirzepatide Treatment for an Obese Patient with Obstructive Sleep Apnea: A Case Report. Obes Facts. 2026:1-4. PubMed 42378200 · PMC13451026 · doi:10.1159/000553125
  12. Zhang X, Jiang Y, Wei X, et al. Incretin-Based Therapies in Obesity-Related Obstructive Sleep Apnea: A Narrative Review of Evidence Tiers and Mechanistic Plausibility. Nat Sci Sleep. 2026;18:611573. PubMed 42591103 · PMC13461384 · doi:10.2147/NSS.S611573
  13. Falcon B, Xie CC, Redline S, et al. Association of tirzepatide with changes in OSA-related measures based on baseline characteristics – post hoc analyses of SURMOUNT-OSA. J Clin Sleep Med. 2026;22(1):155. PubMed 42675225 · PMC13530102 · doi:10.1007/s44470-026-00162-z
  14. Kanu C, Shinde S, Falcon B, et al. Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: post-hoc analyses. Sleep. 2026;49(10):zsag184. PubMed 42412744 · PMC13658257 · doi:10.1093/sleep/zsag184
  15. Shinde S, Kanu C, Varnado OJ, et al. Patients' Experiences of Obstructive Sleep Apnea and Tirzepatide Treatment: An Exit Interview Study. Patient. 2026;19(4):601-614. PubMed 41793578 · PMC13287229 · doi:10.1007/s40271-026-00808-3
  16. Beccuti G, Bioletto F, Parasiliti-Caprino M, et al. Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials. Curr Obes Rep. 2024;13(4):739-742. PubMed 39378016 · PMC11522180 · doi:10.1007/s13679-024-00592-x
  17. Rai P, Bathla G, Praveen N, et al. GLP-1 receptor agonists in obstructive sleep apnea: A propensity score-matched real-world analysis. Respir Med. 2026;261:109001. PubMed 42362122 · doi:10.1016/j.rmed.2026.109001
  18. Carvalhal G, Mora MMR, Peralta-Jiménez GA, et al. GLP-1 receptor agonists for obstructive sleep apnea: a meta-analysis of randomized controlled trials. Sleep Breath. 2026;30(5):279. PubMed 42837024 · doi:10.1007/s11325-026-03826-5
  19. Chiappa GR, Santos PCN, Cavalcante DVS, et al. Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: A network meta-analysis of randomised trials. Diabetes Obes Metab. 2026;28(5):3557-3567. PubMed 41725443 · doi:10.1111/dom.70572

Leave a Comment

Your email address will not be published. Required fields are marked *